Clinical trial
A Study With LY293111, Gemcitabine and Placebo in Patients With Pancreatic…
NCT00055250 · Eli Lilly and Company, Industry · Completed
Key facts
| NCT number | NCT00055250 |
|---|---|
| Title | A Study With LY293111, Gemcitabine and Placebo in Patients With Pancreatic Cancer |
| Official title | A Randomized, Placebo-Controlled, Double-Blind Phase 2 Study of Gemcitabine Plus LY293111 Compared to Gemcitabine Plus Placebo in Patients With Locally Advanced or Metastatic Pancreatic Cancer |
| Lead sponsor | Eli Lilly and Company, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Pancreatic Cancer |
| Intervention type | Drug |
| Interventions | Gemcitabine, LY293111, placebo |
| Enrollment | 130 |
| Start date | Jan 1, 2003 |
| Completion | Oct 1, 2005 |
| First posted | Feb 24, 2003 |
| Last update posted | Jan 26, 2007 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: